Leukotriene receptor antagonists
CysLT1 receptor blockade (montelukast)
- Response rate
- Modest in AERD subtype
- Onset
- Weeks
- Route
- Oral 10mg daily
- Line
- Adjunctive
- IgM effect
- Minimal
Evidence summary
Most effective in AERD subtype where cysteinyl leukotriene overproduction drives disease. Montelukast can reduce polyp size and improve symptoms in this subset. Limited efficacy in non-AERD CRSwNP.